Clinical Trial Update: Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating weekly paclitaxel plus gemcitabine as second-line therapy for small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED